Get Live Data

The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses
Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licensesView Video

Latest Share Chat

  2. Share Prices
  3. Allergy Thera. Share Price
  4. Allergy Thera. Share Regulatory News

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Allergy Thera. Information

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.85
Bid: 2.80
Ask: 2.90
Change: 0.00 (0.00%)
Spread: 0.10 (3.571%)
Open: 2.85
High: 2.85
Low: 2.85
Prev. Close: 2.85
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

34567891011
Date   Source Headline
13th May 20196:14 pmRNSHolding(s) in Company
13th May 20194:41 pmRNSSecond Price Monitoring Extn
13th May 20194:35 pmRNSPrice Monitoring Extension
7th May 20197:00 amRNSResearch Published on Adjuvant Systems
25th Apr 20197:00 amRNSRegulatory and Trading Update
18th Mar 20194:41 pmRNSSecond Price Monitoring Extn
18th Mar 20194:36 pmRNSPrice Monitoring Extension
18th Mar 201911:30 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Take an objective view
18th Mar 201911:05 amRNSSecond Price Monitoring Extn
18th Mar 201911:00 amRNSPrice Monitoring Extension
18th Mar 20199:05 amRNSSecond Price Monitoring Extn
18th Mar 20199:00 amRNSPrice Monitoring Extension
18th Mar 20197:00 amRNSTop Line Phase III results from B301 trial
6th Mar 201912:10 pmEQSHardman & Co Research: Allergy Therapeutics (AGY): Strong operating performance driving market share
6th Mar 20197:00 amRNSInterim Results
17th Jan 20199:56 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Trading update: gaining market share
16th Jan 20197:00 amRNSTrading Update & Notice of Results
29th Nov 20185:59 pmRNSHoldings in Company
27th Nov 20181:12 pmRNSResult of AGM
27th Nov 20187:00 amRNSAGM Trading Update
12th Nov 201812:00 pmRNSPresentation at Jefferies Healthcare Conference
8th Nov 20187:00 amRNSDirectorate Change
7th Nov 20186:06 pmRNSHoldings in Company
2nd Nov 20187:00 amRNSGrant of Awards under Long Term Incentive Plan
24th Oct 20181:25 pmRNSHoldings in Company
24th Oct 20187:00 amRNSDirector/PDMR Shareholding
23rd Oct 20185:29 pmRNSAnnual Report and Accounts
23rd Oct 20183:28 pmRNSHoldings in Company
27th Sep 20187:15 amEQSHardman & Co Research: Allergy Therapeutics (AGY): 2018 full-year results: solid growth
26th Sep 20187:00 amRNSPreliminary Results
8th Aug 20187:00 amRNSNotice of Results
27th Jul 20185:26 pmRNSHolding(s) in Company
26th Jul 201812:02 pmRNSHolding(s) in Company
19th Jul 201810:19 amRNSResults of Placing and Subscription
19th Jul 20187:00 amRNSProposed placing & subscription to raise £10.6m
16th Jul 20188:53 amRNSBLOCK LISTING SIX MONTHLY RETURN
13th Jul 20189:40 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Steady performance in a tough market
12th Jul 20187:00 amRNSTrading Update
25th Jun 20187:52 amRNSPositive data of Pollinex Quattro Grass vaccine
29th May 20187:00 amRNSPositive data with house-dust mite immunotherapy
21st May 201812:25 pmEQSHardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registration
21st May 20187:00 amRNSPositive top-line results from Grass Ph II study
14th May 20187:00 amRNSPublication of MCT Adjuvant Data
16th Mar 20183:38 pmRNSGrant of Awards under Long Term Incentive Plan
16th Mar 201812:53 pmRNSDirector/PDMR Shareholding
7th Mar 20189:30 amRNSHardman: Clinical development towards submission
7th Mar 20187:00 amRNSInterim Results
28th Feb 20187:00 amRNSPolyvac® Peanut CMO appointed
12th Feb 20187:00 amRNSCompletion of recruitment in PQ Grass Ph II trial
2nd Feb 20187:15 amRNSHardman Research: Growth in a tough market
34567891011

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.